MARKET

SGMT

SGMT

Sagimet Biosciences Inc.
NASDAQ
6.05
+0.02
+0.33%
After Hours: 6.24 +0.19 +3.06% 17:30 12/16 EST
OPEN
6.01
PREV CLOSE
6.03
HIGH
6.31
LOW
5.87
VOLUME
897.16K
TURNOVER
--
52 WEEK HIGH
11.41
52 WEEK LOW
1.730
MARKET CAP
196.76M
P/E (TTM)
-3.3865
1D
5D
1M
3M
1Y
5Y
1D
Tracking Baker Brothers Portfolio - Q3 2025 Update
Seeking Alpha · 9h ago
Weekly Report: what happened at SGMT last week (1208-1212)?
Weekly Report · 1d ago
Sagimet Biosciences announces China’s NMPA accepted NDA for denifanstat
TipRanks · 6d ago
Sagimet's License Partner Ascletis Pharma Issues Statement That China's National Medical Products Administration Accepts NDA For Denifanstat For Acne Treatment
Benzinga · 6d ago
China's NMPA Accepts Ascletis' NDA for Sagimet's Denifanstat in Moderate to Severe Acne
Reuters · 6d ago
SAGIMET BIOSCIENCES INC - GRANTS EXCLUSIVE LICENSE TO DENIFANSTAT FOR CHINA TO ASCLETIS
Reuters · 6d ago
SAGIMET’S LICENSE PARTNER ASCLETIS ANNOUNCED ACCEPTANCE OF NEW DRUG APPLICATION FOR DENIFANSTAT FOR THE TREATMENT OF MODERATE TO SEVERE ACNE BY CHINA’S NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Reuters · 6d ago
Sagimet Biosciences Grants Stock Options to New Employees
Reuters · 12/09 21:05
More
About SGMT
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.

Webull offers Sagimet Biosciences Inc stock information, including NASDAQ: SGMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SGMT stock methods without spending real money on the virtual paper trading platform.